5 Key Takeaways
-
1
The November 2026 listing covers active clinical trials in age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and uveitis.
-
2
The listing reports that trials of RO7669330 for geographic atrophy and REGN7041 for active noninfectious uveitis were terminated.
-
3
A new phase 3 study will assess OCU410 for geographic atrophy secondary to dry age-related macular degeneration in 237 participants.
-
4
New geographic atrophy studies include phase 2 trials of oral STL303 and FWY003, with planned enrollment of 300 and 272 participants, respectively.
-
5
Other newly listed studies examine imaging, dietary intervention, anesthesia for intravitreal injections, gene therapy, and SGLT2 inhibitors.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.